Introduction. The purpose of this study was to determine the feasibility of human Papillomavirus (HPV) testing alone as a prognostic tool to predict recurrent disease within a three-year follow-up period after treatment for cervical intraepithelial neoplasia (CIN)2 + . Material and methods. Retrospectively, 128 women with histologically verified CIN2 + who had a conization performed at Southern Jutland Hospital in Denmark between 1 January 2013 and 31 December 2013 were included. Histology, cytology and HPV test results were obtained for a three-year follow-up period. Results. 4.7% (6/128) of the cases developed recurrent disease during follow-up. Of the cases without free margins, recurrent dysplasia was detected normal in 10.4% (5/48), whereas in the group with free margins it was 1.3% (1/80). The post-conization HPV test was negative in 67.2% (86/128) and Pap smear normal in 93.7% (120/128). Combining resection margins, cytology and HPV had sensitivity for prediction of recurrent dysplasia of 100%. Specificity was 45.8%, positive predictive value (PPV) 8.5% and negative predictive value (NPV) 100%. Using HPV test alone as a predictor of recurrent dysplasia gave a sensitivity of 83.3%, specificity 69.7%, PPV 11.9% and NPV 98.8%. Combining resection margin and HPV test had a sensitivity of 100%, specificity 45.9%, PPV 8.3% and NPV 100%. Conclusion. HPV test at six months control post-conization gave an NPV of 98.8% and can be used as a solitary test to identify women at risk for recurrent disease three years after treatment for precursor lesions. Using both resection margin and HPV test had a sensitivity of 100% and NPV 100%. Adding cytology did not increase the predictive value.
Introduction
Women treated for cervical intraepithelial neoplasia (CIN)2 + with conization have a markedly increased risk for residual and recurrent disease and invasive cancer (1, 2) . The majority of recurrent lesions are seen within two years of treatment but the risk is continuously increased (3) .
Follow-up after treatment of precursor lesions is important to catch recurrent lesions but it must be balanced to avoid unnecessary long follow-up periods and adverse psychological outcomes (4) .
Key message
Using only margin status and HPV test in surveillance post-treatment for CIN2
+ yields an equally high sensitivity and negative predictive value as a combination of cytology, HPV test and resection margin status. Cytology could be omitted from post-treatment management without lowering negative predictive value.
Through the years, several strategies for follow-up after treatment for precursor lesions have been proposed. Some of those frequently used are cytological examination of a cell sample from cervix uteri combined with colposcopy (with or without biopsy), information about the resection margin and test for human Papillomavirus (HPV) (5) . In recent years a great deal of the focus has been on the significance of HPV testing and the combination of HPV test and cytology after cone biopsy (6) (7) (8) (9) , as cervical cytology has been found to have a relatively low sensitivity (7, 10) . Several studies have demonstrated that HPV test 6-12 months after conization can be used for surveillance, as HPV testing is more sensitive than cytology and it has a very high (97%-100%) negative predictive value (NPV) (11) (12) (13) . A positive HPV test at any time during follow-up has been identified as the most significant independent predictor of recurrent disease in the management of adenocarcinoma in situ (14) .
It seems that HPV testing could be a useful strategy for managing follow-up after treatment for precursor lesion and may permit a shortening of the follow-up period necessary (15) (16) (17) , but so far there is no international consensus regarding the number of tests and follow-up visits necessary in the post-treatment surveillance (18) .
Many complex combinations of test results can be seen and it is necessary to establish a principle that ensures guidelines that promote rational and consistent management (19) . If two different management scenarios yield the same risk of precancer/cancer, these two scenarios should be managed equally -"equal management of equal risks" (20) . CIN3 + has been suggested as the best surrogate of invasive cancer risk (20) . CIN3 + is considered superior to CIN2 + , as CIN2 diagnoses are poorly reducible, the risk of progression to CIN3 + lesions is only moderate and many CIN2 + lesions regress spontaneously (21, 22) . It has been argued that a three-year CIN3 + risk less than 2.0% is acceptable to recommend return to the usual screening program for cervical cancer (20) .
In Denmark, the Danish National Board of Health has published recommendations for screening for cervical cancer and follow-up after treatment of precursor lesion. A combination of cytology and HPV testing is recommended along with information about resection margin. If the margins at resection site were not involved, cytology did not reveal abnormal cells and the HPV test was negative at the first control six months after conization, it is recommended to return to the national screening program. In the screening program, women aged 23-49 years are invited for cervical screening every three years and women aged 50-64 years every five years. Women aged 60 years and over are withdrawn from the program if the HPV test is negative. Were any of the three parameters (margins, cytology and HPV test) abnormal after conization, the woman would be enrolled in a closer follow-up program with control at a gynecologist every 6-12 months depending on the results (Figure 1 ) (23) .
It has been shown that combined testing at the postconization visit is not statistically significantly more sensitive than HPV testing alone, raising the question of whether HPV testing could stand alone in the follow-up after treatment of precursor lesion (24) . Emerging data suggest that HPV test post-conization effectively distinguishes women who are at risk of residual and recurrent disease from those who are not, and that post-treatment management guidelines for women with a negative HPV test could be simplified (25) . If it is possible to lower the number of unnecessary cytological samples and reduce the number of follow-up visits for HPV-negative women with resection margins not involved, this could reduce the workload at pathology departments. The resulting savings can then be directed towards the high-risk women.
The Danish National Board of Health has also recommended the use of the three-tier CIN terminology in histology and the Bethesda terminology in cytology.
The aim of this study was to determine whether HPV testing could stand alone as a clinical prognostic tool for identifying women at risk for recurrent disease three years after treatment for precursor lesions.
Material and methods
This retrospective study included women who had a conization performed at Southern Jutland Hospital in Denmark between 1 January 2013 and 31 December 2013. The women were identified in The National Pathology Data Bank (Patobanken), a computerized nationwide register containing the results of all examinations performed at pathology departments in Denmark. The classification system used is the Systematized Nomenclature of Medicine (SNOMED); the code T83701 for cone was used to identify the cases. Histology, cytology and HPV test results for each case were recorded for a three-year follow-up period ending 31 December 2016.
The inclusion criterion was cervical conization. Cases without histologically confirmed CIN2 + pre-conization or at conization were excluded. Cases without an HPV test result at the first control after treatment were excluded. Another two cases were excluded due to post-conization hysterectomy. This resulted in a study population of 128 women ( Figure 2 ).
Reviewed data included: age at conization; resection margin; HPV test result post-conization and, if available, pre-conization; follow-up Pap smears and/or biopsies.
Cases with unclear or not evaluable margins were rubricated as cases with involved margins, as per the recommendations of the Danish National Board of Health.
Cytology was sampled and processed routinely as SurePath© Pap-smears (BD, Franklin Lakes, NJ, USA). HPV-DNA testing was carried out routinely on Cobas 4800 (Roche, Pleasanton, CA, USA).
Step sectioning was performed routinely on all cervical punch biopsies.
Recurrent disease was defined as residual or recurrent histologically confirmed CIN2 + in the follow-up period.
Statistical analyses
Statistical analyses were performed using STATA version 12.0 (StataCorp LP, College Station, TX, USA). Data were analyzed using Fisher's exact test to evaluated differences in proportions. A p-value <0.05 was considered statistically significant. Sensitivity, specificity, positive predictive value (PPV) and NPV was used to determine the diagnostic accuracy of resection margin, cytology, HPV testing and co-testing as detection tools after conization.
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Results
Characteristics of the study groups are listed in Table 1 . The mean age of the 128 women was 35.6 years (range 20-77). Surgical margins were not free in 48 (37.5%) of the 128 cases. Recurrent dysplasia was detected in five of these 48 cases (10.4%), vs. only one case of recurrent dysplasia among the 80 cases with free margins (1.3%). This difference is statistically significant (p = 0.028).
A pre-conization HPV test result was available for 49 women, all of them positive for HPV. HPV types 16 and/ or 18 were the most prevalent types (63.3%).
A post-conization HPV test was negative for high-risk types HPV in 86 (67.2%) of the 128 cases. Eleven cases (8.6%) tested positive for HPV type 16 and/or 18. Thirtyone cases (24.2%) were tested positive for other high-risk HPV types.
A Pap smear at first post-conization control was normal for 124 (93.7%) women. One woman had atypical squamous cells that could not exclude HSIL (ASCH): four low-grade squamous intraepithelial lesions (LSIL) and one high-grade squamous intraepithelial lesion (HSIL). One smear was unsatisfactory for evaluation and one was not available.
Six (4.7%) of the 128 cases developed recurrent disease during the follow-up period. Of these six cases, one had uninvolved resection margins at conization, three (50.0%) had a normal Pap smear at the first control and one (16.7%) had a negative HPV test at first control after conization. The latter case had a negative Pap smear as well at the first control, but the margins were involved. At the second control, ASCH was found on Pap smear and the HPV test was type 16-positive. Punch biopsies at the third control revealed CIN3; the subsequent re-conization was diagnosed as a squamous cell carcinoma.
Combining resection margins, cytology and HPV gave a sensitivity for prediction of recurrent dysplasia of 100%. Specificity was 45.8%, PPV 8.5% and NPV 100%. Using only HPV test as a predictor of recurrent dysplasia gave a sensitivity of 83.3%, specificity of 69.7%, PPV of 11.9% and NPV of 98.8%. Combining cytology and HPV test gave a sensitivity of 83.3%, specificity of 69.2%, of PPV 11.9% and NPV of 98.8%. Combining cytology and status for resection margins gave a sensitivity of 83.3%, specificity of 63.3%, PPV of 10.2% and NPV of 98.7%. A free resection margin and a negative HPV test without cytology had a sensitivity of 100%, specificity of 45.9%, PPV of 8.3% and NPV of 100% (Table 2 ).
Discussion
Recurrent disease is an important concern after conization for CIN. In this study, six of the 128 cases (4.7%) developed recurrent dysplasia. This is in concordance with previous reports (16, (26) (27) (28) .
HPV testing is a credible tool in the post-treatment surveillance period. A Swedish study has recently shown that a negative co-test (HPV and cytology) six months after conization can be considered a reliable test of cure (29) . Based on the principles of risk stratification it would be acceptable to return to screening with a three-year CIN2 + risk of less than 2% (20) and HPV testing alone can provide this. To simplify the follow-up algorithm, we suggest cytology could be used as a triage test for HPV-positive women to decide on either direct referral to colposcopy or annual co-testing until benign cytology and a negative HPV test (Figure 3) . In this minor cohort we have shown that, following The Danish Guidelines (updated 2012), combining information about the resection margins, cytology and HPV testing gives a sensitivity and NPV of 100%. Furthermore, both sensitivity and NPV decrease (to 83.3 and 98.8%, respectively) when only using the HPV test as a predictor of recurrent dysplasia. This is slightly lower than a recent Italian study showing that an HPV test six months after treatment had an NPV of 100% five years post-treatment (25) .
Using only information about the resection margins and HPV status and not cytology gives an equally high sensitivity and NPV (both 100%) as combining resection margin status, cytology and HPV testing. One could thus argue that information about the resection margins and HPV test at first control post-conization is the best way to predict disease eradication.
However, as the prevalence of recurrent dysplasia is low in the minor cohort we investigated, it is crucial to evaluate differences in NPV with caution.
Some studies state that margin status adds little to HPV testing (30) and to cytology (3) in targeting woman at risk for recurrent disease, whereas others highlight the importance of having information about the possible involvement of resection margins, since incomplete excision of CIN is a risk factor of recurrent/residual disease (7, 31) . A recent meta-analysis confirms that involvement of resection margins significantly increases the risk of residual or recurrent disease but also establishes that a positive HPV test post-treatment predicts treatment failure more accurately compared with margin status (32). Arbyn and colleagues found that 6.6% of women treated for CIN2 + had residual or recurrent disease, a slightly higher number than our 4.7%.
In this study, one case with recurrent disease had both a negative Pap smear and a negative HPV test at the first post-conization control. However, the resection margins in this case were involved, which ensured inclusion in a closer follow-up program. Combining margin status and post-treatment HPV status could be used to stratify risk and enable different management decisions in accordance with patient characteristics, the strategy also supported by Arby and colleagues (32) .
The current guidelines from European Federation of Colposcopy suggest that ≥85% of conizations contain CIN2 + (33) . In our study this performance indicator was fulfilled, with CIN2 + in 96% (123/128) of the cones.
Furthermore, the European Federation of Colposcopy suggests that resection margins should be free in ≥80% of conizations. In many studies, this indicator has not yet been achieved (32) . In our study, 62.5% (80/128) cones had free resection margins. Several factors may influence the status of the margins; the gynecologist's experience, size of the lesion and the patient's age. An important consideration is the risk of obstetrical complications -the larger excisions the higher frequency and severity of adverse effect (34) .
In conclusion, this study shows that HPV testing gives an NPV on 98.8% as a clinical prognostic tool for identifying women at risk for recurrent disease three years after treatment for precursor lesions. Based on the theory of "equal risk -equal management", a three-year risk for CIN2 + lesions of less than 2% is considered acceptable to recommend a return to the screening program. Therefore, HPV testing alone can be used to identify women at risk for recurrent disease three years after treatment for precursor lesions.
When including resection margin status and HPV testing at first control post-conization, the sensitivity and NPV are equivalent to the method currently used in Denmark, which includes cytology + HPV co-testing in combination with the assessment of surgical margins. However, the specificity is lower when combining HPV test and margins status than when using HPV testing alone.
If a combination of margin status and post-treatment HPV status is to be used to stratify risk and enable different management decisions, further research and larger studies are needed to find the best strategy for follow-up of CIN2 + -treated patient before modification of the follow-up management guidelines can be implemented.
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